Sugi Predict

Sugi Predict / Compounds / SCHEMBL9903112

SCHEMBL9903112

SCHEMBL9903112

C#Cc1c(F)cccc1F

nearest known ligand 0.36

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ CES2 O00748 2/20 0.36
▸ CES1 P23141 2/20 0.36
▸ KDM4E B2RXH2 3/20 0.33
▸ TAAR1 Q96RJ0 1/20 0.33
▸ ACHE P22303 1/20 0.33
▸ ALDH1A1 P00352 1/20 0.33
▸ HPGD P15428 1/20 0.33
▸ HSD17B10 Q99714 1/20 0.33
▸ BCHE P06276 1/20 0.32
▸ NFE2L2 Q16236 3/20 0.32
▸ L3MBTL1 Q9Y468 1/20 0.32
▸ GAA P10253 1/20 0.31
▸ CYP1A1 P04798 1/20 0.31
▸ CYP1B1 Q16678 1/20 0.31
▸ CYP19A1 P11511 1/20 0.30
▸ ALB P02768 1/20 0.30
▸ ERN1 O75460 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14248398 0.85 TAAR1 (0.42) KDM4ETAAR1ALDH1A1GAA
SCHEMBL17086513 0.83 CYP3A4 (0.35) CES2CES1TAAR1ALDH1A1HPGD
SCHEMBL1459645 0.83 ACHE (0.48) CES2CES1ACHEALDH1A1L3MBTL1
SCHEMBL3228382 0.83 L3MBTL1 (0.31) CES2CES1L3MBTL1
SCHEMBL18297590 0.83 CES2 (0.30) CES2CES1
SCHEMBL28306824 0.79 TSHR (0.36) KDM4EALDH1A1HPGDHSD17B10L3MBTL1
SCHEMBL16956590 0.79 L3MBTL1 (0.30) L3MBTL1
SCHEMBL18297484 0.79 KDM4E (0.38) KDM4EALDH1A1HPGDHSD17B10L3MBTL1
SCHEMBL28307768 0.78 GRM5 (0.39) KDM4EL3MBTL1
SCHEMBL24653160 0.78 ERN1 (0.52) ALDH1A1HPGDNFE2L2ERN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 79 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260022094-A1 Compounds for the Treatment of Neurodegenerative Diseases CELGENE CORPORATION (US) 2026-01-22 — — US disclosed
EP-4558480-A1 COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES CELGENE CORPORATION (US) 2025-05-28 — — EP disclosed
CN-120019042-A Compounds for the treatment of neurodegenerative diseases 细胞基因公司 2025-05-16 — — CN disclosed
EP-4400172-A2 PIPERIDIN-4-YL AZETIDINE DERIVATIVES AS JAK1 INHIBITORS Incyte Holdings Corporation (US) 2024-07-17 — — EP disclosed
CN-115052860-B Collagen 1 translation inhibitors and methods of use thereof 艾尼莫生物科技公司 2024-06-21 — — CN disclosed
CN-115710215-B Phenylethynyl substituted benzenes and heterocycles for the treatment of cancer and uses thereof 肯塔基大学研究基金会 2024-06-04 — — CN disclosed
CN-115650904-B Phenylethynyl substituted benzenes and heterocycles for the treatment of cancer and uses thereof 肯塔基大学研究基金会 2024-05-14 — — CN disclosed
WO-2024019957-A1 COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES CELGENE CORPORATION (US) 2024-01-25 — — WO disclosed
WO-2024019957-A1 COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES CELGENE CORPORATION (US) 2024-01-25 — — WO disclosed
US-20230318037-A1 METHOD FOR PREPARING A LITHIUM ION SECONDARY BATTERY AND A LITHIUM ION SECONDARY BATTERY PREPARED THEREFROM MURATA MANUFACTURING CO., LTD. (JP) 2023-10-05 — — US disclosed
US-20140179682-A1 METABOTROPHIC GLUTAMATE RECEPTOR 5 MODULATORS AND METHODS OF USE THEREOF SUNOVION PHARMACEUTICALS INC. (US) 2014-06-26 — — US disclosed
EP-2738172-A1 New bicyclic compounds as crac channel modulators Almirall, S.A. (ES) 2014-06-04 — — EP disclosed
US-20140142084-A1 NITROGEN-CONTAINING AROMATIC HETEROCYCLIC COMPOUND KOTOBUKI PHARMACEUTICAL CO., LTD. (JP) 2014-05-22 — — US disclosed
US-20140142084-A1 NITROGEN-CONTAINING AROMATIC HETEROCYCLIC COMPOUND KOTOBUKI PHARMACEUTICAL CO., LTD. (JP) 2014-05-22 — — US disclosed
WO-2013129369-A1 NITROGEN-CONTAINING AROMATIC HETEROCYCLIC COMPOUND アステラス製薬株式会社 (JP) 2013-09-06 — — WO disclosed
WO-2012172093-A1 DIHYDROINDOLIZINE DERIVATE AS METABOTROPIC GLUTAMATE RECEPTOR MODULATORS MERZ PHARMA GMBH & CO. KGAA (DE) 2012-12-20 — — WO disclosed
WO-2012170845-A2 METABOTROPIC GLUTAMATE RECEPTOR 5 MODULATORS AND METHODS OF USE THEREOF HEFFERNAN MICHELE L R (US) 2012-12-13 — — WO disclosed
US-20120178742-A1 METABOTROPIC GLUTAMATE RECEPTOR MODULATORS MERZ PHARMA GMBH & CO. KGAA (DE) 2012-07-12 — — US disclosed
EP-2462142-A1 METABOTROPIC GLUTAMATE RECEPTOR MODULATORS Merz Pharma GmbH & Co. KGaA (DE) 2012-06-13 — — EP disclosed
CN-102471334-A Metabotropic glutamate receptor modulators MERZ PHARMA GMBH & CO KGAA 2012-05-23 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120178742-A1 METABOTROPIC GLUTAMATE RECEPTOR MODULATORS GRM5, GRIK5, GRM1 CES2 2673/4885CES1 3062/4885KDM4E 1958/4885
US-20140142084-A1 NITROGEN-CONTAINING AROMATIC HETEROCYCLIC COMPOUND FGFR3, FGFR1, FGFR2 CES2 4398/4885CES1 4368/4885KDM4E 553/4885
US-20260022094-A1 Compounds for the Treatment of Neurodegenerative Diseases S1PR5, CLN6, S1PR1 CES2 488/4885CES1 450/4885KDM4E 2571/4885
US-20140179682-A1 METABOTROPHIC GLUTAMATE RECEPTOR 5 MODULATORS AND METHODS OF USE THEREOF GRM5, GRIK5, GRM2 CES2 862/4885CES1 940/4885KDM4E 3093/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.